Why Your GLP-1 Weight Loss Might Be Plateauing Every patients weight management journey is unique
doi: 10.1016/j.neuroscience.2015.06.054 Summary Keywords Parkinsons disease, diabetes, glucagon-like peptide 1, insulin, energy metabolism, neuroprotection Citation Lv D, Feng P, Guan X, Liu Z, Li D, Xue C, Bai B and Hlscher C (2024) Neuroprotective effects of GLP-1 class drugs in Parkinsons disease
Key findings from the Phase 2 trial included: Dose-dependent reductions in body weight across all active treatment arms Significant improvements in waist circumference, a key marker of visceral adiposity Reductions in fasting insulin levels and HbA1c Improvements in lipid profiles, including triglycerides Phase 3 trials are currently ongoing and are expected to include larger, more diverse populations with more granular subgroup analyses, including sex-specific data
You cant escape it on your social media feeds. On the lack of safety and efficacy data for BPC-157 Jarry: Ill give you an example of one which is quite popular
Wegovy uses a semaglutide base with strict quality controls
For more tips, check out our article: Dietitian Tips for Drinking More Water Each Day